Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2022 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present Preclinical Data on XMT-1660, XMT-2056 and the Immunosynthen Platform at AACR Annual Meeting

XMT-1660 demonstrates robust activity in preclinical models of breast cancer XMT-2056 demonstrates robust activity as monotherapy, in combination with standard of care therapies and in both HER2-high...
March 15, 2022 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present an Analysis from the Expansion Cohort of the Phase 1 Trial of Upifitamab Rilsodotin at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
March 02, 2022 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at the Cowen 42nd Annual Health Care Conference

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
February 28, 2022 06:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

UPLIFT on track to complete enrollment Q3 2022, UP-NEXT to initiate in Q2 2022, and UPGRADE on track for 2H 2022 interim data readoutXMT-1660 and XMT-2056 expected to enter clinic mid-2022Research...
February 22, 2022 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2021 Financial Results and Business Updates

CAMBRIDGE, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
February 10, 2022 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
February 03, 2022 07:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Research Collaboration and License Agreement with Janssen to Advance Novel Antibody-Drug Conjugates

Collaboration focused on discovering novel ADCs for three targets by leveraging Mersana’s ADC expertise and the Dolasynthen platform with Janssen’s proprietary antibodiesMersana receives $40 million...
January 07, 2022 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces 2022 Strategic Priorities and Milestones

UPLIFT, a single-arm registrational trial of UpRi in platinum-resistant ovarian cancer, expected to complete enrollment in Q3 2022 UP-NEXT, a Phase 3 trial of UpRi monotherapy maintenance in...
January 05, 2022 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...
December 02, 2021 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Named to 2021 List of Top Places to Work in Massachusetts by The Boston Globe

CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...